88 related articles for article (PubMed ID: 8507076)
1. p53 Protein expression in nevi and melanomas.
Cristofolini M; Boi S; Girlando S; Zumiani G; Cristofolini P; Dalla Palma P; Doglioni C; Barbareschi M
Arch Dermatol; 1993 Jun; 129(6):739-43. PubMed ID: 8507076
[TBL] [Abstract][Full Text] [Related]
2. Concurrent Ki-67 and p53 immunolabeling in cutaneous melanocytic neoplasms: an adjunct for recognition of the vertical growth phase in malignant melanomas?
Kaleem Z; Lind AC; Humphrey PA; Sueper RH; Swanson PE; Ritter JH; Wick MR
Mod Pathol; 2000 Mar; 13(3):217-22. PubMed ID: 10757331
[TBL] [Abstract][Full Text] [Related]
3. Expression of cell cycle and apoptosis regulatory proteins and telomerase in melanocitic lesions.
Batinac T; Hadzisejdić I; Brumini G; Ruzić A; Vojniković B; Zamolo G
Coll Antropol; 2007 Jan; 31 Suppl 1():17-22. PubMed ID: 17469743
[TBL] [Abstract][Full Text] [Related]
4. S100A6 protein expression is different in Spitz nevi and melanomas.
Ribé A; McNutt NS
Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
[TBL] [Abstract][Full Text] [Related]
5. Ki-67 and p53 expression in minimal deviation melanomas as compared with other nevomelanocytic lesions.
Chorny JA; Barr RJ; Kyshtoobayeva A; Jakowatz J; Reed RJ
Mod Pathol; 2003 Jun; 16(6):525-9. PubMed ID: 12808056
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas.
Kanter-Lewensohn L; Hedblad MA; Wejde J; Larsson O
Mod Pathol; 1997 Sep; 10(9):917-20. PubMed ID: 9310955
[TBL] [Abstract][Full Text] [Related]
7. G1 cell cycle regulators in congenital melanocytic nevi. Comparison with acquired nevi and melanomas.
Stefanaki C; Stefanaki K; Antoniou C; Argyrakos T; Stratigos A; Patereli A; Katsambas A
J Cutan Pathol; 2008 Sep; 35(9):799-808. PubMed ID: 18494826
[TBL] [Abstract][Full Text] [Related]
8. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
Boyd AS; Shakhtour B; Shyr Y
J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
[TBL] [Abstract][Full Text] [Related]
9. Proteins involved in pRb and p53 pathways are differentially expressed in thin and thick superficial spreading melanomas.
de Sá BC; Fugimori ML; Ribeiro Kde C; Duprat Neto JP; Neves RI; Landman G
Melanoma Res; 2009 Jun; 19(3):135-41. PubMed ID: 19369901
[TBL] [Abstract][Full Text] [Related]
10. Cdc7 expression in melanomas, Spitz tumors and melanocytic nevi.
Clarke LE; Fountaine TJ; Hennessy J; Bruggeman RD; Clarke JT; Mauger DT; Helm KF
J Cutan Pathol; 2009 Apr; 36(4):433-8. PubMed ID: 19278428
[TBL] [Abstract][Full Text] [Related]
11. p53 expression in cutaneous malignant melanoma: an immunohistochemical study of 87 cases of primary, recurrent, and metastatic melanoma.
Barnhill RL; Castresana JS; Rubio MP; Martin MT; Idoate M; Vazquez JJ; Thor AD
Mod Pathol; 1994 Jun; 7(5):533-5. PubMed ID: 7937717
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of vascular endothelial growth factor, matrix metalloproteinase 2, and matrix metalloproteinase 9 in cutaneous melanocytic lesions.
Simonetti O; Lucarini G; Brancorsini D; Nita P; Bernardini ML; Biagini G; Offidani A
Cancer; 2002 Nov; 95(9):1963-70. PubMed ID: 12404291
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of p53 is a late event in the development of malignant melanoma.
Lassam NJ; From L; Kahn HJ
Cancer Res; 1993 May; 53(10 Suppl):2235-8. PubMed ID: 8485708
[TBL] [Abstract][Full Text] [Related]
14. Expression of protease-activated receptors 1 and 2 in melanocytic nevi and malignant melanoma.
Massi D; Naldini A; Ardinghi C; Carraro F; Franchi A; Paglierani M; Tarantini F; Ketabchi S; Cirino G; Hollenberg MD; Geppetti P; Santucci M
Hum Pathol; 2005 Jun; 36(6):676-85. PubMed ID: 16021575
[TBL] [Abstract][Full Text] [Related]
15. Histologic and epidemiologic correlates of P-MAPK, Brn-2, pRb, p53, and p16 immunostaining in cutaneous melanomas.
Richmond-Sinclair NM; Lee E; Cummings MC; Williamson R; Muller K; Green AC; Hayward NK; Whiteman DC
Melanoma Res; 2008 Oct; 18(5):336-45. PubMed ID: 18781132
[TBL] [Abstract][Full Text] [Related]
16. Cell cycle and apoptosis regulators in Spitz nevi: comparison with melanomas and common nevi.
Stefanaki C; Stefanaki K; Antoniou C; Argyrakos T; Patereli A; Stratigos A; Katsambas A
J Am Acad Dermatol; 2007 May; 56(5):815-24. PubMed ID: 17437889
[TBL] [Abstract][Full Text] [Related]
17. Proto-oncogene c-kit expression in malignant melanoma: protein loss with tumor progression.
Montone KT; van Belle P; Elenitsas R; Elder DE
Mod Pathol; 1997 Sep; 10(9):939-44. PubMed ID: 9310959
[TBL] [Abstract][Full Text] [Related]
18. A high percentage of skin melanoma cells expresses SPANX proteins.
Salemi M; Calogero AE; Vicari E; Migliore E; Zaccarello G; Cosentino A; Amore M; Tricoli D; Castiglione R; Bosco P; Rappazzo G
Am J Dermatopathol; 2009 Apr; 31(2):182-6. PubMed ID: 19318807
[TBL] [Abstract][Full Text] [Related]
19. Survivin protein in UVB induced apoptosis of melanoma cells and in melanoma progression.
Zhang H
Oncol Rep; 2005 Jun; 13(6):1121-6. PubMed ID: 15870931
[TBL] [Abstract][Full Text] [Related]
20. Comparison of pHH3, Ki-67, and survivin immunoreactivity in benign and malignant melanocytic lesions.
Nasr MR; El-Zammar O
Am J Dermatopathol; 2008 Apr; 30(2):117-22. PubMed ID: 18360113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]